STAT+: Pharmalittle: We’re reading about Wegovy supplies, Biogen ditching Aduhelm, and more

Rise and shine, everyone. The middle of the week is upon us. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? And what better way to make the time fly than to keep busy. So grab that cup of stimulation and get started. Our flavor today is glazed doughnut — sweets for the sweet, you know? Meanwhile, do keep us in mind if you hear anything interesting. We hope you have a simply smashing day and emerge unscathed. …

Novo Nordisk has begun to increase availability of its blockbuster obesity drug Wegovy for new patients in the U.S. after massive demand and a supply crunch had led it to limit doses last May, STAT writes. The announcement concerning the lower-dose starter product came as the company reported 2023 sales rose 36% and operating profit grew…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks